- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vaccines in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need. Development of one or more herpes simplex virus (HSV) vaccines is an important objective for sexual and reproductive health worldwide. HSV vaccine PPCs describe global public health goals for HSV vaccines and preferred parameters pertaining to vaccine indications and target populations, safety and efficacy considerations, research and development, and immunization strategies.
Keywords: HIV, HSV, diagnosis, vaccine, public health
WHO estimates that 71 million people worldwide were chronically infected with hepatitis C virus (HCV) in 2017. Globally, 23% of new HCV infections and one in three HCV deaths are attributable to injecting drug use (PWID). HCV is also a major concern for people detained in prisons and other closed settings – available data demonstrate that one in four detainees are HCV positive.
This policy brief highlights the current landscape of country hepatitis policies for harm reduction and HCV testing and treatment in PWID and people in prisons. It aims to capture how governments are translating the WHO Global health sector strategy on viral hepatitis, 2016-2021 into national plans, and provides a summary of the enablers and barriers to HCV testing and treatment in these populations.
The Global Fund to Fight AIDS, TB and Malaria has opened up the opportunity to incorporate tobacco control into TB and HIV grants. In line with the 2030 Agenda, the UNDP Strategic Plan 2018-2021, and UNDP’s HIV, Health and Development Strategy 2016-21: Connecting the Dots, UNDP and the Secretariat of the WHO Framework Convention on Tobacco Control (WHO FCTC) have produced this Issue Brief to inform Global Fund applicants on integrating tobacco cessation into Global Fund HIV and TB grants. The Issue Brief outlines how tobacco consumption worsens TB and HIV outcomes and how the integration of tobacco control could increase health benefits and efficiencies. Key approaches and practical options for such integration are outlined, based on a review of research and case studies.
Keywords: TB, HIV, SDGs, response, tobacco
Due to its characteristics, widespread cultivation and use, and diversity of its applications the Cannabis sativa L. plant directly pertains to at least 62 of the 169 targets found in 15 out of the 17 Sustainable Development Goals (SDGs). Surprisingly, this plant affects the SDGs both positively and negatively.
This report explains how the “hemp-issues” of Cannabis sativa L. (non psychoactivity-related uses) can contribute to meeting Goals 1, 2, 7, 9, 11, 12, 13 and 15, but also why reforming the current repressive, prohibitive, and marginalizing policies relating to “marijuana-issues” (psychoactivity-related uses of Cannabis sativa L.) is indispensable to meet Goals 3, 4, 5, 8, 10, 13, 16 and 17.
WHO is accountable for reporting back to the World Health Assembly on progress in implementing the Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections based on data received from countries. This report assesses the mid-term progress in 2019 in implementing these global health sector strategies from 2016 to 2021.
The timeliness and availability of the data across the three diseases is limited, being for 2016 or 2017 in most cases. Key data, including 2018 impact data on incidence and mortality, were not available for this report, making it difficult to assess and validate overall trends since the launch of the strategies in 2016.
Keywords: HIV, UHC, STI, hepatitis, diagnosis, treatment, financing
The publication provides information on contraceptive options and choice, the medical eligibility criteria for different methods of contraception for women and adolescent girls living with HIV and using antiretroviral therapy, a summary of the comparative effectiveness of contraceptive methods and contraceptive considerations at different stages of a woman’s life-course.
The 2016 Political Declaration of the High-level Meeting of the United Nations General Assembly on Antimicrobial Resistance represented a landmark in the world’s commitment to tackling antimicrobial resistance, calling for greater urgency and action in response to its many challenges. In the political declaration, Member States requested the Secretary-General, in consultation with the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO) to convene an ad hoc interagency coordination group (IACG) co-chaired by the Executive Office of the Secretary-General and the Director-General of WHO to provide practical guidance for approaches needed to ensure sustained, effective global action to address antimicrobial resistance. It also requested the Secretary-General to submit a report for consideration by Member States by the seventy-third session of the General Assembly in 2019 on the implementation of the political declaration and on further developments and recommendations emanating from the IACG, including on options to improve coordination, considering the 2015 Global Action Plan on Antimicrobial Resistance.
The rise in antimicrobial resistance (AMR) is one of the greatest threats to global health. If it is not urgently addressed, it may result in millions of deaths, an increase in new and hard-to-treat infections and increased health-care costs. As a result, combatting AMR, including the threat posed by drug-resistant HIV, is a major goal for the global community.
Prevention, monitoring and timely response to population levels of HIV drug resistance (HIVDR) is critical to achieving the WHO/UNAIDS 90–90–90 targets for 2020 that 90% of people living with HIV know their HIV status, 90% of those who know their HIV-positive status are accessing treatment and 90% of the people receiving treatment having suppressed viral loads.
Keywords: HIV, antimicrobial resistance (AMR), drug resistance (HIVDR), treatment
The DOH Administrative Order No. 2017-0019 or the Policies and Guidelines in the Conduct of Human Immunodeficiency Virus (HIV) Testing Services (HTS) in Health Facilities defines HIV Treatment hubs as a hospital with an organized HIV and AIDS Core Team (HACT) that facilitates in-patient and out-patient prevention, treatment, care and support services to PLHIV including but not limited to antiretroviral therapy, HIV testing services, clinical management, patient monitoring, and other care and support services.
This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.